Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide metabolic and cardiorenal benefits for patients with type 2 diabetes but are associated with a number of safety issues. Here, we discuss evidence suggesting that indirect activation of the FGF23–1,25-dihydroxyvitamin D–parathyroid hormone axis by SGLT2 inhibition might contribute to adverse effects on bone health.
J.E.B. is supported by funding from the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). S.I.T. acknowledges funding from the NIDDK (grant number P30DK072488).